Saturday, June 19, 2021

Characterization Techniques for Nanoparticles Enabled Medicinal Products

The number of innovative nanoparticles enabled medicinal products (NEMPs) being developed has been continually increasing.[66] Multiple regulatory bodies[67-71] implicitly demand product assessment in their quality, safety and efficacy in order to support their decision-making process, allowing effective translation toward a clinical application and subsequent commercialization.[67-71]

With their small sizes, nanoparticles (NPs) present unique opportunities and challenges in both manufacturing and analysis:[72]
If compared with ‘classical’ small molecule drugs, the assessment for NEMPs demands the investigation of many additional physico-chemical (PC) properties, including particle size distribution and polydispersity, dispersion stability, drug loading and drug release, particle shape, surface charge, surface coating, among many others.
To complicate matters, each NEMP is unique, imposing different methodological approaches to characterize its PC properties and to determine the critical quality attributes, which could impact its immunological effects, biodistribution, pharmacokinetics, metabolism and safety profile.
For example, measurements of particle size and zeta potential are routinely performed on the same instrument by dynamic light scattering (DLS) and laser Doppler electrophoresis (LDE), but require multiple experiments, and are challenged by polydisperse samples, for example, exosomes isolated from body fluids.

In this article, we will focus on three such characterization techniques for:
  • Particle Size Distribution
  • Surface Charge
  • Surface Coating
Figure 1.  Antibody conjugated PLGA Nanoparticle


Properties of Nanoparticles


The reason why nanoparticles (NPs) are attractive for medical purposes is based on their important and unique features:
  • Nanosize
    • The small particle diameter allows the whole material to reach homogeneous equilibrium with respect to diffusion in a very short time.
      • Small drugs may diffuse through the capillary walls into the tissues. Otherwise nanoparticles transport occurs through compromised endothelial barrier or mediated by specific transport systems.
    • The small size not only makes them needle-injectable, but also enhance penetration through tissue barriers.
  • Large area/volume ratio
    • The high surface area of a material in nanoparticle form allows heat, molecules, and ions to diffuse into or out of the particles at very large rates.
    • Offers a large surface area for bioconjugation and effortless natural clearance
  • Ability to absorb and carry other compounds
    • Drugs can be conjugated to nanoparticles surfaces via ionic or covalent bonding and physical absorption and NPs can deliver them and control their release through biological stimuli or other activations (see Figure 1).
  • More subject to the brownian motion
    • They usually do not sediment, like colloidal particles that conversely are usually understood to range from 1 to 1000 nm.
  • Can easily pass through common filters (e.g., common ceramic candles)
  • Cannot be seen with optical microscopes
With consistent efforts, researchers have strived to engineer these NPs by modifying their physical and chemical properties, referring to them as ‘smart’ or ‘intelligent’ NPs since they respond to external stimuli like temperature, pH, light, magnetic and electric fields, ionic strength, or enzymatic environment.

Particle Size Distribution


The particle size distribution (PSD) and the stability of NEMPs in complex biological environments are key attributes to assess their quality, safety and efficacy.
Nanoparticle's chemical, electronic, optical, magnetic and catalytic, properties, and self-assembly, inherently depend on their size and composition.[73-79]
There are different methods to measure the nanoparticle size:
  1. Dynamic light scattering
    • Despite its low resolution, DLS is the most common sizing technique
  2. Electron microscopy
  3. Field flow fractionation coupled to online sizing detectors
  4. Centrifugal techniques
    • Ultracentrifugation, one of the most commonly used concentration methods, is time consuming and suffers from contamination.[80,81]
    • Size-based filtration through membranes can result in deformations or even break the particles.[80,82]
  5. Particle tracking analysis
  6. Nanoparticle tracking analysis
  7. Tunable Resistive Pulse Sensing
In a perspective article,[65] it proposes a multi-step approach of incremental complexity to measure particle size distribution and size stability of NEMPs, consisting of:
  1. A quick preliminary step to assess sample integrity and stability by low resolution techniques (pre-screening)
  2. Followed by the combination of complementary high resolution sizing measurements performed both in simple buffers and in complex biological media

Surface Charge


The surface charge of nanoparticles is important as it determines its
  • Stability
  • Propensity to aggregate in the bloodstream
  • Interacting with the cell membranes
Zeta potential is a measure of the surface charge of a nanoparticle. The magnitude of the zeta potential provides information about particle stability:
In a sense, the zeta potential represents an index for particle stability. For charged particles, as the zeta potential increases the repulsive interactions becomes larger, leading to stable particles, likely to have a more uniform size distribution.
The zeta potential of particles is typically measured by Electrophoretic Light Scattering (ELS).[89] In contrast to streaming potential measurements no movement of the liquid is generated, but the movement of the particles is induced. Therefore, an electric field is applied and the electrophoretic mobility of particles is used to calculate the zeta potential. Due to the electric field particles will move at different speeds: highly charged particles will move faster than less charged particles. 


Figure 2. Core-shell nanoparticles: perspectives towards drug delivery applications (source: [88]).
In the review article,[88] it explores state-of-the-art developments and advances in core–shell nanoparticle systems, the desired structure–property relationships, newly generated properties, the effects of parameter control, surface modification, and functionalization, and, last but not least, their promising applications in the fields of drug delivery, biomedical applications, and tissue engineering.


Surface Coating


Nanosystems have shown encouraging outcomes and substantial progress in the areas of drug delivery and biomedical applications. In this regard, core–shell type nanoparticles are promising nanocarrier systems for controlled and targeted drug delivery applications.
These functional nanoparticles are emerging as a particular class of nanosystems because of their unique advantages, including high surface area, and easy surface modification and functionalization. Such unique advantages can facilitate the use of core–shell nanoparticles for the selective mingling of two or more different functional properties in a single nanosystem to achieve the desired physicochemical properties that are essential for effective targeted drug delivery.
Several types of core–shell nanoparticles, such as metallic, magnetic, silica-based, upconversion, and carbon-based core–shell nanoparticles, have been designed and developed for drug delivery applications (see Figure 2).
Nanoparticles often develop or receive coatings of other substances, distinct from both the particle's material and of the surrounding medium. Even when only a single molecule thick, these coatings can radically change the particles' properties, such as and chemical reactivity, catalytic activity, and stability in suspension.
Many properties of nanoparticles, notably stability, solubility, and chemical or biological activity, can be radically altered by coating them with various substances — a process called functionalization.

For biological applications,
  • Coatings that mimic those of red blood cells can help nanoparticles evade the immune system.[86,90]
  • Coating should be polar to give high aqueous solubility and prevent nanoparticle aggregation.
    • In serum or on the cell surface, highly charged coatings promote non-specific binding, whereas polyethylene glycol linked to terminal hydroxyl or methoxy groups repel non-specific interactions.[83,84]
  • Coatings can be used to prevent agglomeration
    • Which can keep the particles in colloidal suspension including various polymers like polyethylene glycol (PEG), poly(vinylpyrrolidone) (PVP) etc, natural polymers like dextran, chitosan, pullulan etc, and surfactants like sodium oleate, dodecylamine etc.[85]

By consideration of surface energy, it is shown that these particles are expected to possess distinctly differing coating structures, with the polystyrene coating being incomplete. A comprehensive characterization of these systems can be done using a selection of complementary techniques including:

By combining the results provided by these techniques, it is possible to achieve superior characterization and understanding of the particle structure than could be obtained by considering results separately.[87]

References

  1. Nanoparticles—a historical perspective
  2. Preparation and Characterization of Cross-Linked Polymeric Nanoparticles for Enhanced Oil Recovery Applications (pdf)
  3. Polyacrylamide and its deriv ylamide and its derivatives for oil r es for oil recovery (pdf)
  4. Nanosizing of drugs: Effect on dissolution rate
  5. Development and functional characterization of alginate dressing as potential protein delivery system for wound healing
  6. Designing hydrogels for controlled drug delivery (good)
  7. Novavax addresses urgent global public health needs with innovative technology
  8. How the Novavax Vaccine Works
  9. Widder KJ, Senyel AE, Scarpelli GD. Magnetic microspheres: a model system of site specific drug delivery in vivo. Proc Soc Exp Biol Med. 1978;158:141–6.
  10. Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation
  11. Methods for Synthesis of Nanoparticles and Fabrication of Nanocomposites
  12. NANOPARTICULATE DRUG DELIVERY SYSTEM
  13. Switchable Release of Entrapped Nanoparticles from Alginate Hydrogels.[Adv Healthc Mater. 2015]
  14. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Vinogradov SV, Bronich TK, Kabanov AV. Adv Drug Deliv Rev. 2002 Jan 17; 54(1):135-47.
  15. Applications of Targeted Nano Drugs and Delivery Systems
  16. Langer R. Drug delivery and targeting. Nature. 1998;392:5–10.
  17. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. Polymer. 2008;49:1993–2007.
  18. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Ann Rev Chem Biomol Eng. 2010;1:149–173.
  19. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908–908.
  20. Florence AT, Jani PU. Novel oral drug formulations. Drug Safety. 1994;10:233–266.
  21. Ashley GW, Henise J, Reid R, Santi DV. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. Proc Natl Acad Sci USA. 2013;110:2318–2323.
  22. Tiwari G, et al. Drug delivery systems: An updated review. Int J Pharm Investig. 2012;2:2–11.
  23. Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc.
  24. Singh, BN; Prateeksha, Gupta VK; Chen, J; Atanasov, AG (2017). "Organic Nanoparticle-Based Combinatory Approaches for Gene Therapy". Trends Biotechnol. 35 (12): 1121–1124. 2016;138:704–717.
  25. Wang, Zhenming; Wang, Zhefeng; Lu, William Weijia; Zhen, Wanxin; Yang, Dazhi; Peng, Songlin (October 2017). "Novel biomaterial strategies for controlled growth factor delivery for biomedical applications"
  26. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009;8:15–23.
  27. Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev. 2006;35:1095–1104.
  28. Gratton SE, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA. 2008;105:11613–11618.
  29. Geng H, Song H, Qi J, Cui D. Sustained release of VEGF from PLGA nanoparticles embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix. Nanoscale Res Lett. 2011;6:1–8.
  30. Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K. The development of microgels/nanogels for drug delivery applications. Prog Polym Sci. 2008;33:448–477.
  31. Crommelin DJ, Storm G. Liposomes: from the bench to the bed. J Liposome Res. 2003;13:33–6.
  32. Metselaar JM, Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv. 2005;2:465–76.
  33. Noh SY, Nash A, Notman R (2020). "The aggregation of striped nanoparticles in mixed phospholipid bilayers". Nanoscale. 12 (8): 4868–81.
  34. Nanotechnologies: 6. What are potential harmful effects of nanoparticles?
  35. Thake, T.H.F; Webb, J.R; Nash, A.; Rappoport, J.Z.; Notman, R. (2013). "Permeation of polystyrene nanoparticles across model lipid bilayer membranes". Soft Matter. 9 (43): 10265 10274.
  36. Greulich, C.; Diendorf, J.; Simon, T.; Eggeler, G.; Epple, M.; Köller, M. (January 2011). "Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells". Acta Biomaterialia. 7 (1): 347–354.
  37. Compartmentalization Technologies via Self-Assembly and Cross-Linking of Amphiphilic Random Block Copolymers in Water
  38. Drug delivery and nanoparticles: Applications and hazards (good)
  39. The pKa Table Is Your Friend (important)
  40. Nanoparticles as a Targeted Drug Delivery System
  41. Self-Assembled Hydrogel Nanoparticles for Drug Delivery Applications
  42. Gupta M, Gupta AK. In vitro cytotoxicity studies of hydrogel pullulan nanoparticles prepared by AOT/N-hexane micellar system. J Pharm Pharmaceut Sci. 2004;7:38–46.
  43. Biocompatibility and drug delivery systems (good)
  44. S. R. Little and D. S. Kohane, Polymers for intracellular delivery of nucleic acids, J. Mater. Chem., 2008, 18, 832–841
  45. Polymeric Nucleic Acid Delivery for Immunoengineering
  46. Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Delivery Rev. 2002;54:631–651.
  47. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Delivery Rev. 2003;55:329–347.Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001;53:283–318.
  48. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001;53:283–318.
  49. Sun T.-M., Du J.-Z., Yan L.-F., Mao H.-Q., Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials. 2008;29:4348–4355.
  50. Jain A.K., Goyal A.K., Gupta P.N., Khatri K., Mishra N., Mehta A., Mangal S., Vyas S.P. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J. Control. Release. 2009;136:161–169.
  51. Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114:343–7.
  52. M. Goldberg, R. Langer and X. Jia, Nanostructured materials for applications in drug delivery and tissue engineering, J. Biomater. Sci., Polym. Ed., 2007, 18, 241–268.
  53. D. S. Kohane, Microparticles and nanoparticles for drug delivery, Biotechnol. Bioeng., 2007, 96, 203–209
  54. What Are Lipid Nanoparticles in mRNA Vaccines?
  55. Plard J.P., Bazile D. Comparison of the safety profiles of PLA(50) and Me.PEG-PLA(50) nanoparticles after single dose intravenous administration to rat. Colloids Surf. B. 1999;16:173–183.
  56. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release. 1999;60:121–128.
  57. Matsumura Y., Maeda H. A New Concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs1. Cancer Res. 1986;46:6387–6392.
  58. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Delivery Rev. 2004;56:1649–1659.
  59. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: Current status and future prospects. FASEB J. 2005;19:311–330.
  60. Fang C, Shi B, Pei YY, et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27–36.
  61. Shim J, Seok Kang H, Park WS, et al. Transdermal delivery of minoxidil with block copolymer nanoparticles. J Control Release. 2004;97:477–84.
  62. Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release. 2004;96:135–48.
  63. A programmable chemical switch based on triggerable Michael acceptors
  64. SELF-IMMOLATIVE CHEMISTRY: Structural Features and Applications in Designing Smart Materials (pdf)
  65. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity
  66. D’Mello SR, Cruz CN, Chen ML, Kapoor M, Lee SL, Tyner KM. The evolving landscape of drug products containing nanomaterials in the United States. Nat. Nanotechnol. 12(6), 523–529 (2017).
  67. US FDA. Guidance Document: Drug Products, Including Biological Products, that Contain Nanomaterials – Guidance for Industry.
  68. EMA. Development of Block-Copolymer-Micelle Medicinal Products (Reference Number EMA/CHMP/130299/2013).
  69. EMA (Committee for Medicinal Products for Human Use). Reflection Paper on the Data Requirements for Intravenous Iron-Based Nano-Colloidal Products Developed with Reference to an Innovator Medicinal Product (2012).
  70. Committee for Human Medicinal Products. Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to Aninnovator Liposomal Product (2013).
  71. US FDA. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation (2018).
  72. Nano-enabled medicinal products: time for an international advanced community?
  73. El-Sayed, M. A. Some interesting properties of metals confined in time and nanometer space of different shapes. Accounts Chem. Res. 34, 257–264 (2001).
  74. Trindade, T., O'Brien, P. & Pickett, N. L. Nanocrystalline semiconductors: synthesis, properties and perspectives. Chem. Mater. 13, 3843–3858 (2001).
  75. Kelly, K. L., Coronado, E., Zhao, L. L. & Schatz, G. C. The optical properties of metal nanoparticles: the influence of size, shape, and dielectric environment. J. Phys. Chem. B. 107, 668–677 (2003).
  76. Seo, W. S. et al. Size-dependent magnetic properties of colloidal Mn3O4 and MnO nanoparticles. Angew. Chem. Int. Ed. 43, 1115–1117 (2004).
  77. Mohanty, A., Garg, N. & Jin, R. A universal approach to the synthesis of noble metal nanodendrites and their catalytic properties. Angew. Chem. Int. Ed. 49, 4962–4966 (2010).
  78. Rao, C. N. R., Kulkarni, G. U., Thomas, P. J. & Edwards, P. P. Size-dependent chemistry: properties of nanocrystals. Chem. Eur. J. 8, 29–35 (2002).
  79. Boal, A. K. et al. Self-assembly of nanoparticles into structured spherical and network aggregates. Nature 404, 746–748 (2000).
  80. Li, P., Kaslan, M., Lee, S. H., Yao, J. & Gao, Z. Progress in exosome isolation techniques. Theranostics 7, 789 (2017).
  81. Lane, R. E., Korbie, D., Anderson, W., Vaidyanathan, R. & Trau, M. Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci. Rep. 5, 7639 (2015).
  82. Batrakova, E. V. & Kim, M. S. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control. Rel. 219, 396–405 (2015).
  83. Prime, KL; Whitesides, GM (1991). "Self-assembled organic monolayers: model systems for studying adsorption of proteins at surfaces". Science. 252 (5009): 1164–7.
  84. Liu, Wenhao; Greytak, Andrew B.; Lee, Jungmin; Wong, Cliff R.; Park, Jongnam; Marshall, Lisa F.; Jiang, Wen; Curtin, Peter N.; Ting, Alice Y.; Nocera, Daniel G.; Fukumura, Dai; Jain, Rakesh K.; Bawendi, Moungi G. (20 January 2010). "Compact Biocompatible Quantum Dots via RAFT-Mediated Synthesis of Imidazole-Based Random Copolymer Ligand". Journal of the American Chemical Society. 132 (2): 472–483.
  85. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995–4021.
  86. "Nanoparticles play at being red blood cells". Archived from the original on 1 July 2011. Retrieved 1 July 2011.
  87. Surface-Energy Control and Characterization of Nanoparticle Coatings
  88. Core–shell nanostructures: perspectives towards drug delivery applications
  89. Anton Paar. (n.d.) Faster, More Sensitive Zeta-Potential Measurements with cmPALS and the Litesizer™ 500. [January 24 2019]. Bellmann, C., Caspari, A., Moitzi, C., Fradler, C., Babick, F. (2018) DLS & ELS Guide. Luxbacher, T. (2014)
  90. Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
              Posted by at

              No comments:

              Post a Comment

              Subscribe to: Post Comments (Atom)